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Significance of pregnancy-associated plasma protein A (PAPP-A)
concentration determination in the assessment of final outcome of
pregnancy
Znaþaj odreÿivanja koncentracije plazma proteina trudnoüe A (PAPP-A) u
proceni konaþnog ishoda trudnoüe
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Gynecology and Obstetrics Clinic, Clinical Centre Kragujevac,
Kragujevac, Serbia
Abstract
Background/Aim. Pregnancy-associated plasma protein
A (PAPP-A) is high molecular matrix metalloproteinase
originally isolated in the serum of pregnant women. The
aim of this study was to analyze the values of concentra-
tion of PAPP-A in assessment of progress and outcome of
pregnancy in pregnant women diagnosed with threatening
preterm delivery, preeclampsia and fetal growth restriction
in relation to physiological pregnancy of the same gesta-
tional age. Methods. The study included 60 pregnant
women that were divided into three groups according to
gestational age and the diagnosis of imminent premature
birth upon reception, preeclampsia and fetal growth re-
striction as follows: the group I from 28 to 32 weeks of
gestation, a total of 25 pregnant women, the group II from
33 to 36 weeks of gestation, a total of 23 pregnant women,
and the group III from 37 to 41 weeks of gestation, a total
of 12 pregnant women. The control group consisted of 60
pregnant women without complications of pregnancy that
were identically divided into three groups according to
gestational age as in the sample. We performed quantita-
tive determination of PAPP-A from the venous blood of
patients by using commercial tests of the company Diag-
nostics Product Corporation (DPC), Los Angeles, Califor-
nia, USA. Results. There was a statistically significant dif-
ference in PAPP-A values in the examined groups in all
gestational ages (p < 0.01). The value of the PAPP-A con-
centration in different gestational ages with equal statistical
significance indicated the possibility of complications,
which was examined during pregnancy in relation to the
control group of pregnant women with physiological
pregnancies. This study confirmed that there was a statisti-
cally significant difference in fetal body weight at birth (p
< 0.05), Apgar score in 5 min after birth (p < 0.05), and
gestational age at birth (p < 0.05), as parameters of  the
outcome of pregnancy course, between the examined
groups of pregnant women in relation to the value of
PAPP-A concentration. The age of pregnant women was
not statistically different in the examined groups (p >
0.05). Conclusion. Differences in PAPP-A concentration
should point out to the obstetrician the need for more in-
tensive antepartum fetal surveillance in order to increase the
chances of favorable perinatal outcome, regardless gesta-
tional age.
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Apstrakt
Uvod/Cilj. Plazma protein A povezan sa trudnoýom
pregnancy-associated plasma protein A (PAPP-A) je visokomole-
kularna matriks metaloproteinaza koja je prvobitno izolova-
na iz seruma trudnih žena. Cilj istrǭživǭnjǭ bio je anǭliza
vrednosti koncentracije PAPP-A u proceni toka i ishoda
trudnoýe kod trudnica sa dijagnozom preteýeg prevremenog
poroĀaja, preeklampsije i zastoja u rastu ploda u odnosu na
fiziološke trudnoýe iste gestacijske starosti. Metode. U stu-
diju je bilo ukljuÿeno 60 trudnica koje su bile podeljene u tri
grupe prema gestacijskoj starosti i prijemnoj dijagnozi pre-
teýeg prevremenog poroĀaja, preeklampsije i zastoja u rastu
ploda: grupa I od 28 do 32 nedelje gestacije imala je ukupno
25 trudnica, grupa II od 33 do 36 nedelja gestacije, ukupno
23 trudnice, i grupa III od 37 do 41 nedelje gestacije, ukup-
no 12 trudnica. Kontrolnu grupu ÿinilo je 60 trudnica bez
ispitivanih komplikacija podeljenih prema gestacijskoj staro-
sti identiÿno kao i u eksperimentalnoj grupi. Kvǭntitǭtivno
odreĀivǭnje PAPP-A vršeno je iz venske krvi bolesnice pri-
menom komercijǭlnih testovǭ firme Diagnostics Product
Corporation (DPC), Los AnĀeles, Kalifornija, USA. Re-Volumen 70, Broj 1 VOJNOSANITETSKI PREGLED Strana 47
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zultati. Postojala je statistiÿki znaÿajna razlika u vrednosti-
ma PAPP-A u ispitivanim grupama u svim gestacijskim sta-
rostima (p < 0,01). Pokazano je da vrednost koncentracije
PAPP-A, u razliÿitim gestacijskim starostima, sa podjedna-
kom statistiÿkom znaÿajnošýu ukazuje na moguýnost kom-
plikacija koje su ispitivane u toku trudnoýe, u odnosu na
kontrolnu grupu trudnica sa fiziološkim trudnoýama. Istra-
živanje je potvrdilo da je postojala statistiÿki znaÿajna razlika
u telesnoj masi ploda na roĀenju (p < 0,05), Apgar skoru
nakon 5 minuta od roĀenja (p < 0,05) i gestacijskoj starosti
na roĀenju (p < 0,05), kao parametara krajnjeg ishoda toka
trudnoýe, izmeĀu ispitivanih grupa trudnica u odnosu na
vrednost koncentracije PAPP-A. Starost trudnica nije se
statistiÿki razlikovala u ispitivanim grupama (p > 0,05). Za-
kljuÿak. Razlike u koncentraciji PAPP-A treba da ukažu
akušerima na potrebu intenzivnije kontrole fetusa pre poro-
Āaja, kako bi se poveýale šanse za povoljan perinatalni is-
hod, bez obzira na gestacijsku starost.
Kljuÿne reÿi:
trudnoýa, ishod; poroĀaj, prevremeni; plazma protein-
A, udružen sa trudnoýom; preeklampsija; fetus,
zaostajanje u rastu; apgar skala; trudnoýa, razvoj
fetusa.
Introduction
Pregnancy-associated plasma protein A (PAPP-A) is
high molecular matrix metalloproteinase originally isolated
in serum of pregnant women. PAPP-A is a glycoprotein,
macroglobulin, of molecular weight of 800,000 with alpha 2-
electrophoretic mobility, and it is produced in syncytiotro-
phoblast cells of the placenta 
1. Determination of PAPP-A is
performed by radioimmunoassay method (immune test with
isotope). The first radioimmunoassay determination of
PAPP-A was carried out in 1980. Using RIA method it is
possible to determine its presence already 3–4 weeks after
conception and no later than the 6th week of gestation. The
maximum level PAPP-A has at the term delivery. PAPP-A
exerts an inhibitory effect on the enzyme elastase, a protease
located in the granules of neutrophils granulocytes and par-
ticipates in processes that lead to the destruction of proteins.
By direct immunofluorescence, the presence of PAPP-A in
spermatozoid’s heads is determined at about 2%. PAPP-A
exerts an inhibitory effect on fixation of both complements
and coagulation system, as well as on the affinity to heparin.
It is assumed that suppressed level of PAPP-A reduces the
zinc ion that is required in the fetal organogenesis, which
represents one of the factors for the occurrence of congenital
malformations. During pregnancy, PAPP-A concentration in
maternal blood increases. Decreased concentration is related
to increased incidence of chromosomal abnormalities in
early gestation and in later pregnancy course because of the
associated placental insufficiency. It is characterized by the
appearance of fetal growth restriction, preeclampsia, preterm
delivery and stillbirth. PAPP-A is a regulator of bioactivity
of insulin-like growth factor 
2. Testing of the role of PAPP-A
in other tissues of the organism has started recently. In-
creased values of PAPP-A were found in patients with acute
coronary syndrom in contrast to healthy population and those
with a diagnosis of stable angina pectoris. It is important to
mention that PAPP-A, which is in circulation of patients with
coronary disease is circulating in free form, whereas in preg-
nant women a complex of PAPP-A and the proform of eo-
sinophil major basic protein is present 
3–5. This brings into
question the adequacy of the used substrates that were syn-
thesized for the detection of complex form of PAPP-A.
PAPP-A represents a useful biomarker in clinical monitoring
of pregnancy course. However, new prospective studies are
needed by using appropriate substrates for the detection of
PAPP-A in order to assess the proper role of metallopro-
teinase in clinical practice. The aim of this study was to
analyze the value of PAPP-A concentration in assessing the
final outcome of pregnancy in pregnant women diagnosed
with threatening preterm delivery, preeclampsia and the fetal
growth restriction in relation to physiological pregnancies of
the same gestational age.
Methods
A prospective, observational study was conducted at the
Gynecology and Obstetrics Clinic, Clinical Center Kra-
gujevac, Kragujevac, Serbia, in 2010. During examination
the clinical–experimental model of study was used. Quanti-
tative measurements of PAPP-A levels were determined
from venous blood of patients using the commercial tests of
the company Diagnostic Product Corporation (DPC), Los
Angeles, California, USA (DPC-USA). The tests, based on
an analytical principle of immunochemiluminescence, were
implemented using the automated analyzer Immulite 2000.
The manufacturer of the analyzer is also DPC-USA.
The study included 60 pregnant women that were di-
vided into three groups according to gestational age and the
diagnosis of imminent premature birth upon reception, pre -
eclampsia and fetal growth restriction as follows: the group I,
from 28 to 32 weeks of gestation, a total of 25 pregnant
women; the group II, from 33 to 36 weeks of gestation, a to-
tal of 23 pregnant women; the group III, from 37 to 41 weeks
of gestation, a total of 12 pregnant women.
The criterion for inclusion of pregnant women in the
study included the previously established all three diagno-
ses that were listed as complications of pregnancy course
according to the following standards: preterm delivery be-
fore the end of 37th week of pregnancy; the diagnosis of
preeclampsia based upon the blood pressure above 140/90
mmHg, proteinuria in 24 hour urine of  0.3 g / per day;
intrauterine growth restriction (IUGR) of fetus was diag-
nosed on the basis of ultrasonographic growth parameters:
biparietal diameter (BPD), transverse trunk diameter
(TTD), head circumference (HC), abdominal circumference
(AC), femur length (FL) and differences in the measured
parameters below the 10th percentile than expected for
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The control group consisted of 60 pregnant women
without complications of pregnancy that were identically di-
vided into three groups according to gestational age as in the
sample. All the obtained results of research were entered into
a single database with valid logic control. Statistical analysis
included calculating the average values and standard devia-
tions (SD) for each numerical parameter and analysis of the
obtained value in relation to the subgroups (t-test, Mann-
Whitney) by using the statistical software SPSS 17.
Results
There was a statistically significant difference of PAPP-
A values in the examined groups in all gestational ages (p <
0.01) (Table 1 and 2 and Figure 1). The mean values and
standard deviations of PAPP-A concentration (mU/mL) in a
total sample of pregnant women diagnosed with threatening
preterm delivery, preeclampsia and intrauterine growth re-
striction were shown in Table 3.
It is found that pregnant women of 28–32 gestational
weeks diagnosed with threatening preterm delivery and pre-
eclampsia, showed significantly lower values PAPP-A than
in healthy pregnant women ( p = 0.001).
Pregnant women of 33–36 gestational weeks diagnosed
with threatening preterm delivery and preeclampsia, showed
significantly lower values of PAPP-A than in healthy preg-
nant women (p = 0.01) (Table 3 and 4).
Pregnant women at term and the diagnosis of pre-
eclampsia, show significantly lower values of PAPP-A than
healthy pregnant women (p = 0.01). Healthy pregnant
women at 28–32 gestational weeks, showed significantly
higher values than pregnant women diagnosed with pre-
eclampsia and intrauterine growth restriction in the same
gestational age. The same comment goes for the t-test in
pregnant women of 33–36 gestational weeks and for a group
of pregnant women with normal term pregnancies (Tables 3
and 4).
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Fig. 1 – Distribution display of pregnancy-associated plasma
protein A (PAPP-A) values in the total sample of pregnant
women in relation to the weeks of gestation
Table 1
Pregnancy-associated plasma protein A (PAPP-A) in the examined pregnant women
 according to fetal age
PAPP-A concentration (mU/mL) Weeks of gestation
(wg)
Number
of women Min Max ʉ ± SD
28–32 25 9,353 304,789 65,930 ± 62,095
33–37 23 424 357,207 103,601 ± 83,987*
> 37 12 37,352 276,849 129,827 ± 60,983*
p < 0.01 vs group 28–32 wg
Table 2
The mean values and standard deviations of the concentration of pregnancy-asociated
plasma protein (PAPP-A) (mU/mL) in the total sample of pregnant women
Weeks of gestation Number of women ʉ ± SD
28–32 25 91,432 ± 48,121
33–36 23 135,061 ± 65,089
> 37 12 154,287 ± 43,458
Table 3
Obstetrics parameters and age in the group of pregnant women with preterm delivery, preeclampsia and intrauterine
growth restriction (n = 60)
Weeks of gestation
(number of women)
Fetal body weight (g)
ʉ r SD
Apgar score/after 5 min
ʉ r  SD
Gestational fetal age at
birth (ng)
ʉ r  SD
Age of the pregnant
woman (year)
ʉ r  SD
28–32 (n = 25) 2,640 ± 110 7.2 ± 0.9 36.0 ± 2.2 26.4 ± 3.1
33–36 (n = 23) 2,750 ± 205 8.0 ± 1.8 38.3 ± 1.8 25.0 ± 2.8
> 37 (n = 12) 3,040 ± 180 8.3 ± 1.4 39.2 ± 3.0 28.2 ± 3.3Volumen 70, Broj 1 VOJNOSANITETSKI PREGLED Strana 49
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Discussion
The aim of this study was to determine the relative risk
for preeclampsia and intrauterine growth restriction at differ-
ent PAPP-A levels in different gestational ages. According to
the literature data, low levels of PAPP-A during the first tri-
mester are associated with the occurrence of preeclampsia
later in the pregnancy 
6. PAPP-A levels in maternal serum
between 11th and 13th week of gestation in 224 singleton
pregnancies, which later developed preeclampsia, were com-
pared to those of 47,770 normal singleton pregnancies that
resulted in live born children after 37 weeks of gestation with
body weights at birth greater or equal to the 10th percentile
in physiological pregnancy 
7. Correlation between the level
of this enzyme and the incidence of preeclampsia was esti-
mated by comparing the relative concentration of PAPP-A at
different gestation.
In the preeclampsia group, the median PAPP-A MoM
was significantly reduced (0.772 MoM, p < 0.0001). With
decreasing level of PAPP-A, a probability ratio for pre-
eclampsia was growing. At the 5th percentile of the normal
(PAPP-A MoM 0.415), the probability rate was increased 4
times 
8, 9. In our sample there was a statistically significant
difference in values of PAPP-A in the examined groups at all
gestational ages (p < 0.01). We showed that the value of
PAPP-A concentration in different gestational ages with
equal statistical significance indicates the possibility of com-
plications examined during pregnancy course in relation to
the control group of pregnant women with normal pregnan-
cies. A probability factor of preeclampsia on any of PAPP-A
MoM levels we consider useful in advising women with low
levels of PAPP-A. The use of low PAPP-A in the prediction
of preeclampsia and growth restriction for selection of
women who will be suggested an intensive surveillance of
pregnancy and therefore significantly reduce the incidence
and mortality morbidity of mother as well as fetus. PAPP-A
is a “protease” for insulin-like growth factor binding proteins
4 and 5. This means that it has the ability to help release in-
sulin-like growth factor from these proteins so that they can
freely interact with their cellular receptors. It is considered
that insulin-like growth factor plays an important role in tro-
phoblast invasion and hence in the early development and
vascularization of the placenta 
10, 11. These early events in the
formation of the placenta are extremely important for the
outcome of pregnancy, and when abnormal, they are associ-
ated with miscarriage, fetal growth restriction, hypertensive
disorders induced by pregnancy (preeclampsia), fetal death
or preterm delivery. It is assumed that low levels of PAPP-A,
leading to reduced release of insulin-like growth factor,
could be a path to placentation abnormalities, culminating in
the adverse outcomes of pregnancy. Spencer et al 
8  in their
study on 54,722 normal singleton pregnancies examined the
role of PAPP-A in the course of pregnancy. At the 5th per-
centile of PAPP-A (0.415 MoM), the probability rate for the
fetus loss before 24 weeks was increased 3.3 times and above
24 weeks 2.8 times. In other words, there was three times in-
creased risk of fetal loss with low levels of PAPP-A. Cowans
and Spencer 
11 have recently confirmed a link between low
PAPP-A and low fetal weight at birth in relation to the ex-
pected for gestational age. In their research they found a linear
association of fetal growth restriction and reduced level of
PAPP-A, in other words, the lower level of PAPP-A, the lower
level of fetal birth weight of any gestational age
 12.
Several other studies confirm the association of other
“complications of pregnancy” listed above with low levels of
PAPP-A 
13–15. For example, as additional results of risk as-
sessment in the first and second trimester (FASTER) study, it
was found that women with concentration of PAPP-A below
the 5th percentile” were significantly more likely to experi-
ence fetal loss before or at the 24th week, low fetal weight at
birth, preeclampsia, gestational hypertension, preterm deliv-
ery (p < 0.001), stillbirth, preterm premature rupture of fetal
membranes and placental abruption (p < 0.02) 
16.
Our research confirmed the allegations of these studies
since we found statistically significant difference in body
weight of the fetus at birth (p < 0.05), Apgar score 5 minutes
after birth (p < 0.05), and gestational age at the time of deliv-
ery (p < 0.05), as parameters of the final pregnancy outcome
between these groups of pregnant women in relation to the
value of the concentration of PAPP-A The age of pregnant
women in our study was not statistically different in the ex-
amined groups (p > 0.05). Despite this association, the posi-
tive predictive value of low level of PAPP-A for one of these
outcomes is still relatively low.
Conclusion
PAPP-A concentration in the pregnant women of 28–36
gestational weeks had significantly lower values with the di-
agnosis of preterm delivery and preeclampsia, than in the
control group. PAPP-A concentration in the pregnant women
diagnosed with preeclampsia in term pregnancy was signifi-
cantly lower than in he healthy pregnant women at term de-
livery. PAPP-A concentration is significantly higher in
physiological pregnancies of 28–36 gestational weeks com-
pared to the concentrations in pregnant women diagnosed
Table 4
Obstetrics parameters and age in the group of pregnant women with normal pregnancies
Weeks of gestation
(number of women)
Fetal body weight (g)
ʉ ± SD
Apgar score/after 5 min
ʉ ± SD
Gestational fetal age at
birth (ng)
ʉ ± SD
Age of the pregnant
woman (year)
ʉ ± SD
28–32 (n = 20) 3,640 ± 210 9.2 ± 0.8 39.1 ± 2.6 27.1 ± 4.4
33–36 (n = 20) 3,550 ± 305 9.0 ± 1.0 38.8 ± 2.9 26.2 ± 1.7
> 37 (n = 20) 3,660 ± 290 9.3 ± 0.7 39.4 ± 2.7 27.3 ± 4.5Strana 50 VOJNOSANITETSKI PREGLED Volumen 70, Broj 1
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with preeclampsia and intrauterine growth restriction, of the
same gestation age. PAPP-A concentration was significantly
higher in physiological pregnancies term gestation in relation
to the concentration in pregnant women diagnosed with pre-
eclampsia and intrauterine growth restriction, of the same
gestation age.
PAPP-A concentration in the examined groups of our
sample had normal distribution due to inhomogeneity of
samples and physiological differences in secretion of en-
zymes in different periods of pregnancy. The pathologic
conditions that we examined additionally influenced the ir-
regularity of PAPP-A distribution.
Considering these limiting parameters, the results of
PAPP-A levels in serum of pregnant women can only have
the screening value, and on the basis of these results, inten-
sive antenatal care should be undertaken.
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